Zhixiang Shen

He Huang, Xiao-jun Huang, Depei Wu, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia

Weili Zhao, Hanzhang Xu, Yingli Wu, 2017, Molecular medicine reports.

Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases

S. Shen, Z. Chen, Bing Chen, 2012, Leukemia.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases

Junmin Li, R. Zhao, Junning Cao, 2012, Annals of Hematology.

Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.

P. Hsueh, Cheng-yi Liu, A. Ong, 2005, International journal of antimicrobial agents.

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Yan Liu, Hua Jiang, B. Jiang, 2017, Cancer Chemotherapy and Pharmacology.

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.

Jiong Hu, Weili Zhao, Huiping Sun, 2016, Blood.

How to manage acute promyelocytic leukemia

Z. Chen, J. Mi, S. Chen, 2012, Leukemia.

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

T. Masszi, F. Nicolini, N. Gallagher, 2012, Leukemia & lymphoma.

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

D. Rizzieri, H. Al-Ali, Dong-Wook Kim, 2009 .

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

D. Rizzieri, H. Al-Ali, Dong-Wook Kim, 2009 .

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group

Junmin Li, X. Hong, Junning Cao, 2012, Annals of Hematology.

The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China

Junmin Li, Weili Zhao, Yang Shen, 2014, Annals of Hematology.

Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients

J. Hou, Wenming Chen, Xiaojun Huang, 2014, Advances in Therapy.

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

C. Niu, J. Chen, W. Wu, 2001, Leukemia.

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Weili Zhao, Jianzhen Shen, Q. Cai, 2021, Frontiers in Oncology.

Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia

C. Niu, Yong-mei Zhu, Saijuan Chen, 2001, Leukemia.